Loading stock data…
¥6,795+181.00 (+2.74%)
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
Chugai Pharmaceutical Co., Ltd. in the Healthcare sector is trading at ¥6,795 with a market capitalization of $11.1T. Wall Street consensus targets ¥8,643 (15 analysts), implying a +27.2% move over the next 12 months. The stock is currently near its 52-week low of ¥5,974, remaining 12.8% below its 200-day moving average. Risk note: RSI 80 is overbought against a weak tape. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (JPY) · Annual | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total Revenue | ¥1.26T↑ | ¥1.11T↓ | ¥1.17T↓ | ¥1.26T |
| Gross Profit | ¥783.48B↑ | ¥698.06B↓ | ¥831.20B↓ | ¥894.25B |
| Operating Income | ¥533.31B↑ | ¥439.17B↓ | ¥542.00B↓ | ¥598.83B |
| Net Income | ¥374.43B↑ | ¥325.47B↓ | ¥387.32B↓ | ¥434.01B |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Ava...